POLE exons 9, 13 and 14 mutational analysis by Sanger sequencing for endometrial carcinomas (DISCONTINUED)

Specimen Requirement	1. Formalin-Fixed Paraffin-Embedded block or 2. 10x unstained sections and 1 corresponding H&E slide. Tissue must be non-necrotic, non-cauterised, and must not have undergone acid-based decalcification. Improper storage conditions may additionally compromise nucleic acid integrity.
Orderable as Urgent?	No
Turn Around Time	7 working days
Testing Laboratory Location	KKH
Laboratory	Molecular Histopathology
Contact Number	6394 1402
Day and Time Performed	Mon – Fri: 0800 hrs– 1700 hrs
Orderable on CPOE?	No
Downtime Form	Molecular Pathology
Additional Information	Background: Endometrial carcinomas can be stratified into four prognostic groups based on molecular features. The “ultramutated” group harbours POLE exonuclease domain mutations (EDM) and is associated with favourable progression-free survival even though histological grade is often high. Purpose of test: The test identifies mutations affecting exons 9, 13 and 14 of the POLE gene. Specimen requirements: 10 unstained sections of tumour and a corresponding H&E-stained histological section, OR a paraffin block of tumour. Turnaround time: 5 working days. Caveats: DNA integrity and concentration must meet assay requirements. Low tumour content (<20%) may result in an inaccurate result. Proficiency testing: Internal quality assurance programme. Reference: Wong A et al. Mutation spectrum of POLE and POLD1 mutations in South East Asian women HT0209

Change History Notes

Last Updated - 27 Jun 2025